Orforglipron

A slew of new medications currently in development may allow health care providers to go beyond glycemic management in the treatment of type 2 diabetes, according to a speaker.

Adults with obesity can lose 15% or more of their body weight with nutrient-stimulated hormone-based therapies, but reducing body weight is not the only goal providers should have when treating obesity, according to a speaker.

The development of incretin-based molecules has led to therapies that can induce greater reductions in HbA1c and body weight for people with type 2 diabetes and obesity than other classes of medication, according to a speaker

DALLAS — In this Healio video exclusive, Ania M. Jastreboff, MD, PhD, highlights several medications that may have a large impact on obesity care in the near future.